Influence of omalizumab on treatment costs for chronic rhinosinusitis with nasal polyps and asthma: an insurance claims analysis

Lauren T. Roland; Sarah K. Wise; Heqiong Wang; Christina Mehta; John M. DelGaudio; Joshua M. Levy

doi:10.1002/alr.22904

Influence of omalizumab on treatment costs for chronic rhinosinusitis with nasal polyps and asthma: an insurance claims analysis

Lauren T. Roland, Sarah K. Wise, Heqiong Wang, Christina Mehta, John M. DelGaudio, Joshua M. Levy

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	310-312
Number of pages	3
Journal	International Forum of Allergy and Rhinology
Volume	12
Issue number	3
DOIs	https://doi.org/10.1002/alr.22904
State	Published - Mar 2022

Access to Document

10.1002/alr.22904

Cite this

@article{c8a10adee8474a6da82ea14f632240e3,

title = "Influence of omalizumab on treatment costs for chronic rhinosinusitis with nasal polyps and asthma: an insurance claims analysis",

author = "Roland, {Lauren T.} and Wise, {Sarah K.} and Heqiong Wang and Christina Mehta and DelGaudio, {John M.} and Levy, {Joshua M.}",

note = "Funding Information: Potential conflicts of interest: L.T.R.: consultant for Tissium; advisory board for GSK, S.K.W.: advisory board for ALK‐Abello, Genentech, OptiNose, and SinopSys Surgical, and consultant for NeurENT, Stryker, and Chitogel; J.M.D.: consultant for Medtronic and ProDex; J.M.L.: advisory board for Sanofi, Regeneron, and GSK, and recipient of research funding from Sanofi, Regeneron, AstraZeneca, Cumberland Pharma, and Optinose. Funding Information: source for the study: AAOA Foundation.",

year = "2022",

month = mar,

doi = "10.1002/alr.22904",

language = "English",

volume = "12",

pages = "310--312",

journal = "International Forum of Allergy and Rhinology",

issn = "2042-6976",

number = "3",

}

TY - JOUR

T1 - Influence of omalizumab on treatment costs for chronic rhinosinusitis with nasal polyps and asthma

T2 - an insurance claims analysis

AU - Roland, Lauren T.

AU - Wise, Sarah K.

AU - Wang, Heqiong

AU - Mehta, Christina

AU - DelGaudio, John M.

AU - Levy, Joshua M.

N1 - Funding Information: Potential conflicts of interest: L.T.R.: consultant for Tissium; advisory board for GSK, S.K.W.: advisory board for ALK‐Abello, Genentech, OptiNose, and SinopSys Surgical, and consultant for NeurENT, Stryker, and Chitogel; J.M.D.: consultant for Medtronic and ProDex; J.M.L.: advisory board for Sanofi, Regeneron, and GSK, and recipient of research funding from Sanofi, Regeneron, AstraZeneca, Cumberland Pharma, and Optinose. Funding Information: source for the study: AAOA Foundation.

PY - 2022/3

Y1 - 2022/3

UR - http://www.scopus.com/inward/record.url?scp=85116212735&partnerID=8YFLogxK

U2 - 10.1002/alr.22904

DO - 10.1002/alr.22904

M3 - Article

C2 - 34596973

AN - SCOPUS:85116212735

SN - 2042-6976

VL - 12

SP - 310

EP - 312

JO - International Forum of Allergy and Rhinology

JF - International Forum of Allergy and Rhinology

IS - 3

ER -

Influence of omalizumab on treatment costs for chronic rhinosinusitis with nasal polyps and asthma: an insurance claims analysis

Access to Document

Other files and links

Cite this